Literature DB >> 9864068

Nitric oxide release mediates vasodilator responses to endomorphin 1 but not nociceptin/OFQ in the hindquarters vascular bed of the rat.

H C Champion1, T J Bivalacqua, D E Friedman, J E Zadina, A J Kastin, P J Kadowitz.   

Abstract

We have recently shown that endomorphin 1, an endogenous ligand for the mu-opioid receptor, and nociceptin (Orphanin FQ; OFQ), an endogenous ligand for the ORL1 receptor, have substantial vasodilator activity in the hindquarters vascular bed of the rat. In the present study, the role of nitric oxide, vasodilator prostaglandins, and the opening of K+ ATP channels in mediating vasodilator responses to endomorphin 1, PL017, and DAMGO was investigated in the regional vascular bed in the rat. Under constant-flow conditions, injections of the mu-selective agonists endomorphin 1, PL017 ([N-MePhe3,D-Pro4]-morphiceptin), and DAMGO, and the ORL1 receptor agonist nociceptin/ OFQ produced dose-dependent decreases in hindquarters perfusion pressure. Vasodilator responses to endomorphin 1, PL017, and DAMGO, and the endothelium-dependent vasodilators acetylcholine and adrenomedullin were attenuated by the nitric oxide synthase inhibitor L-NAME (50 mg/kg IV) at a time when vasodilator responses to nociceptin/OFQ were not altered. Vasodilator responses to isoproterenol and prostaglandin E1, agents known to increase cAMP levels, and the nitric oxide donor DEA/NO were not altered by the nitric oxide synthase inhibitor. Responses to endomorphin 1, PL017, DAMGO, and nociceptin/OFQ were not altered by sodium meclofenamate at a time when vasodilator responses to arachidonic acid were reduced significantly or after administration of U-37883A at a time when vasodilator responses to levcromakalim were reduced significantly. The results of these studies indicate that responses to endomorphin 1, PL017, and DAMGO are mediated in large part by the release of nitric oxide, while responses to nociceptin/OFQ are mediated by an L-NAME-insensitive mechanism. Moreover, these results demonstrate that responses to these peptides are not mediated by the release of vasodilator prostaglandins or the opening of K+ATP channels the hindquarters vascular bed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9864068     DOI: 10.1016/s0196-9781(98)00110-7

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

1.  Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo.

Authors:  H Häbler; L Timmermann; J Stegmann; W Jänig
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  How mental stress affects endothelial function.

Authors:  Noboru Toda; Megumi Nakanishi-Toda
Journal:  Pflugers Arch       Date:  2011-09-23       Impact factor: 3.657

3.  Stimulation of sensory neuropeptide release by nociceptin/orphanin FQ leads to hyperaemia in acutely inflamed rat knees.

Authors:  Chunfen Zhang; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

4.  In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells.

Authors:  Mark F Bird; Barbara Gallacher-Horley; John McDonald; David G McVey; Fatin Al-Janabi; Remo Guerrini; Girolamo Calo; Shu Ye; Jonathan P Thompson; David G Lambert
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

5.  Protection effect of endomorphins on advanced glycation end products induced injury in endothelial cells.

Authors:  Jing Liu; Liping Yan; Ruilan Niu; Limin Tian; Qi Zhang; Jinxing Quan; Hua Liu; Suhong Wei; Qian Guo
Journal:  J Diabetes Res       Date:  2013-04-08       Impact factor: 4.011

6.  Effect of Endomorphins on HUVECs Treated by ox-LDL and Its Related Mechanisms.

Authors:  Juan Zhao; Qi Zhang; Jing Liu; Liming Tian; Wenhui Huang; Jinxing Quan; Jinyang Wang; Yanjia Xu; Yunfang Wang; Ruilan Niu
Journal:  J Diabetes Res       Date:  2016-08-04       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.